Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (2525)	4/20/2000 1:37:00 AM
From: Mad2	Read Replies (2) \| Respond to of 5582

Mike, as a marketer I don't see much difference. both manufacturers have claimes of relief from the symptoms of the common cold, but not a cure. One is in tablet form the other a nazel sprayand both are based on similar technology. Concerning stock price and behavior, QGLY peaked in the fall of 97 in the low/mid 20's and now sells for a buck and a half. They have a market cap of 16mil bucks, whith 14 million in the bank (and no debit), with another 15 mil in recievables and inventory. They're selling for 1/2 the liquidation value and they have 24 mil in sales (with 10 mil shares outstanding thats 2.5 bucks a share. Such are the ways of the broken, fallen, has been small cap stock. Can GUMM duplicate QGLY's fate? Sure, why not. Particularly given the dim prospects for the market in the next 12-18 months. Mike your bullish on GUMM and that's fine, however it's a lot more difficult to push the ball up the hill the second time. mad2